- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.05. | Senti Biosciences Holdings, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| SENTI BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 14.05. | Senti Biosciences GAAP EPS of -$0.14, revenue of $0.01M | 1 | Seeking Alpha | ||
| 14.05. | Senti Bio plans pivotal trial for AML therapy after FDA meeting | 6 | Investing.com | ||
| 14.05. | Senti Biosciences Holdings, Inc. - 8-K, Current Report | 7 | SEC Filings | ||
| 14.05. | Senti Biosciences, Inc.: Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase | 302 | GlobeNewswire (Europe) | Secured strategic financing vehicle for up to $40 million Positive FDA feedback supports single-arm pivotal trial for potential registration of SENTI-202 in initial indication of Relapsed/Refractory... ► Artikel lesen | |
| 14.05. | Senti Biosciences, Inc.: Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 ... | 297 | GlobeNewswire (Europe) | Following a Type B meeting with FDA, Senti Bio plans to proceed with a single-arm multi-center registrational trial for SENTI-202, building off the strong Phase 1 clinical results demonstrating deep... ► Artikel lesen | |
| 08.05. | Senti Biosciences, Inc. - 15-12G, Securities registration termination | - | SEC Filings | ||
| 01.05. | Senti Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 24.04. | Senti Biosciences, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 13.04. | Senti Biosciences, Inc.: Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026 | 5 | GlobeNewswire (USA) | ||
| 01.04. | Senti Biosciences publishes CAR circuit research in Cell Systems | 1 | Investing.com | ||
| 01.04. | Senti Biosciences, Inc.: Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies | 1 | GlobeNewswire (USA) | ||
| 27.03. | Senti Biosciences stock rating held at Buy by H.C. Wainwright | 2 | Investing.com | ||
| 27.03. | Senti Biosciences Non-GAAP EPS of -$0.53 misses by $0.06 | 13 | Seeking Alpha | ||
| 27.03. | Senti Biosciences, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 27.03. | Senti Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.03. | Senti Biosciences, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 20.02. | Senti Biosciences, Inc.: Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development | 3 | GlobeNewswire (USA) | ||
| 11.02. | Senti Biosciences, Inc.: Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) | 181 | GlobeNewswire (Europe) | Robust SENTI-202 clinical data presented at ASH 2025 demonstrated deep, MRD-negative, durable complete remissions and a favorable safety profile Company planning for rapid advancement of SENTI-202... ► Artikel lesen | |
| 14.01. | Senti Biosciences, Inc.: Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company's Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation | 4 | GlobeNewswire (USA) |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,080 | +3,67 % | Aktien im Fokus - Deutsche Telekom: Jetzt oder nie - DEFAMA, Evotec, SFC Energy, Valneva und Verbio | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| MEDIGENE | 0,029 | -6,41 % | PTA-Adhoc: Medigene AG: Widerruf der Zulassung der Aktien der Medigene AG zum Handel im regulierten Markt | DJ PTA-Adhoc: Medigene AG: Widerruf der Zulassung der Aktien der Medigene AG zum Handel im regulierten Markt
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR Schlagwort(e): Sonstiges... ► Artikel lesen | |
| QIAGEN | 30,095 | +0,62 % | QIAGEN N.V.: QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA | Collaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights' curated biomedical knowledge bases Goal to advance how disease mechanisms... ► Artikel lesen | |
| MODERNA | 40,770 | -1,50 % | Moderna to face FDA AdCom review for flu shot | ||
| VALNEVA | 2,517 | +0,84 % | VALNEVA SE - Stabilität als strategische Chance | ||
| STRYKER | 270,00 | -2,35 % | Stryker Buys Amplitude Vascular Systems For Upto $835 Mln To Expand Vascular Treatment Business | WASHINGTON (dpa-AFX) - Tuesday, BioStar Capital announced that Amplitude Vascular Systems, Inc., a medical technology company, has been acquired by Stryker Corporation (SYK) at a purchase price... ► Artikel lesen | |
| ILLUMINA | 123,84 | +1,46 % | RBC Capital assumes Illumina stock coverage with outperform rating | ||
| CRISPR THERAPEUTICS | 42,910 | +2,75 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results | ZUG, Switzerland and BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026. "The first quarter reflected... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 14,380 | -1,17 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 555,20 | -0,63 % | Regeneron Pharmaceuticals-Aktie -12%: Unterschätzen alle diesen Pharmakonzern? | Mit einem Kurssturz von -12% hält die Regeneron Pharmaceuticals-Aktie am Montagmorgen fest die rote Laterne im S&P 500-Index in der Hand. Warum bricht der Kurs des US-Pharmakonzerns zum Wochenbeginn... ► Artikel lesen | |
| BRAIN BIOTECH | 3,120 | +5,05 % | EQS-AFR: BRAIN Biotech AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: BRAIN Biotech AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
BRAIN Biotech AG: Vorabbekanntmachung über... ► Artikel lesen | |
| VIVOSIM LABS | 1,340 | +5,51 % | VivoSim Labs, Inc.: VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales | SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,126 | -100,00 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results | Rolling submission of Biologics License Agreement (BLA) to U.S. Food and Drug Administration (FDA) seeking ST-920 approval is in progress. Six sites activated in Phase 1/2 STAND study evaluating ST-503... ► Artikel lesen | |
| VIKING THERAPEUTICS | 26,400 | +4,14 % | Could Viking Therapeutics Be the Next Eli Lilly? | ||
| INTELLIA THERAPEUTICS | 10,640 | +0,95 % | Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry? |
Das Unternehmen SENTI BIOSCIENCES HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,000 Euro und damit +13,58 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SENTI BIOSCIENCES HOLDINGS INC finden Sie auf Wallstreet Online.